Amicus Therapeutics, Inc.(FOLD) Stock Research - Grey Stern Research
Loading...

Amicus Therapeutics, Inc. (FOLD) Stock Analysis

$11.23 (-4.34%)

FOLD Financial Performance


Use the table below to view Amicus Therapeutics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $11.33 -
52 Week Low $9.02 -
52 Week High $14.57 -
Market Cap $3.4 Billion 12/21
Gross Margin 89% 6/21
Profit Margin -12% 14/21
EBITDA margin 14% 2/21
Q2 - 2024 Revenue $126.7 Million 8/21
Q2 - 2024 Earnings -$15.7 Million 6/21
Q2 - 2024 Free Cash Flow $21.6 Million 3/21
Trailing 4 Quarters Revenue $455.7 Million 7/21
Trailing 4 Quarters Earnings -$119.5 Million 8/21
Quarterly Earnings Growth 64% 6/21
Annual Earnings Growth 41% 5/21
Quarterly Revenue Growth 34% 7/21
Annual Revenue Growth 29% 6/21
Cash On Hand $209.3 Million 12/21
Short Term Debt $8.1 Million 9/21
Long Term Debt $388.9 Million 5/21

Amicus Therapeutics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Amicus Therapeutics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 6/21
PS 7.37 16/21
PB 25.36 2/21
PC 16.05 12/21
Liabilities to Equity 4.66 2/21
ROA -0.16 7/21
ROE -0.90 19/21
Current Ratio 1.21 20/21
Quick Ratio 0.42 21/21
Long Term Debt to Equity 2.93 2/21
Debt to Equity 3.35 2/21
Burn Rate 6.29 6/21
Cash to Cap 0.06 10/21
CCR -1.38 20/21
EV to EBITDA 209.64 1/21
EV to Revenue 7.89 15/21

Company Details

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

CEO: Mr. John Crowley

Website: https://amicusrx.com

Address: 1 Cedarbrook Dr Cranbury, NEW JERSEY

Exchange: NASDAQ Global Market

Industry: Biotechnology

Amicus Therapeutics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Amicus Therapeutics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
BioMarin Pharmaceutical Inc. BMRN $12.6 Billion
Incyte Corporation INCY $14.9 Billion
Dyne Therapeutics, Inc. DYN $2.9 Billion
Denali Therapeutics Inc. DNLI $4.0 Billion
Kura Oncology, Inc. KURA $1.3 Billion
Ultragenyx Pharmaceutical Inc. RARE $4.8 Billion
Blueprint Medicines Corporation BPMC $6.2 Billion
argenx SE ARGX $36.0 Billion
Cytokinetics, Incorporated CYTK $6.2 Billion
Agios Pharmaceuticals, Inc. AGIO $2.7 Billion
Arvinas, Inc. ARVN $1.8 Billion
Crinetics Pharmaceuticals, Inc. CRNX $5.2 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
Revolution Medicines, Inc. RVMD $9.5 Billion
Legend Biotech Corporation LEGN $8.2 Billion
Harmony Biosciences Holdings, Inc. HRMY $1.9 Billion
Inhibrx, Inc. INBX $227.4 Million
Edgewise Therapeutics, Inc. EWTX $3.4 Billion
Day One Biopharmaceuticals, Inc. DAWN $1.5 Billion
DICE Therapeutics, Inc. DICE $2.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
FOLD Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 126.7 Million -$15.7 Million
Q1 2024 $ 110.4 Million -$48.4 Million
Q4 2023 $ 115.1 Million -$33.8 Million
Q3 2023 $ 103.5 Million -$21.6 Million
Q2 2023 $ 94.5 Million -$43.2 Million
Q1 2023 $ 86.3 Million -$52.9 Million
Q4 2022 $ 88.1 Million -$55.9 Million
Q3 2022 $ 81.7 Million -$33.3 Million

View All

FOLD Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $209.3 Million $749.5 Million $444.1 Million $132.5 Million
Q1 2024 $209.8 Million $721.8 Million $444.5 Million $130.7 Million
Q4 2023 $247.0 Million $777.9 Million $445.1 Million $160.2 Million
Q3 2023 $263.3 Million $764.1 Million $454.3 Million $133.2 Million
Q2 2023 $211.3 Million $730.1 Million $452.2 Million $111.6 Million
Q1 2023 $160.6 Million $700.5 Million $452.0 Million $102.6 Million
Q4 2022 $148.8 Million $724.2 Million $452.1 Million $123.0 Million
Q3 2022 $277.6 Million $759.5 Million $450.9 Million $132.6 Million

View All

FOLD Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $21.6 Million -$1.1 Million -$426,000
Q1 2024 -$31.5 Million -$1.8 Million -$37.2 Million
Q4 2023 $1.7 Million -$1.7 Million -$16.3 Million
Q3 2023 -$16.2 Million $0 -$16.2 Million
Q2 2023 -$18.3 Million -$2.2 Million $49.4 Million
Q1 2023 -$20.0 Million -$1.9 Million $11.9 Million
Q4 2022 -$83.4 Million -$2.7 Million -$128.4 Million
Q3 2022 -$11.5 Million $137,000 -$207.8 Million

View All